The group's principal activity is to develop new drugs and improved formulations of existing drugs using proprietary porous microparticle technology. The group develops proprietary drug that offers benefits such as improved safety and efficacy, increased patient compliance and greater ease of use. The group's products are in clinical development and are designed to address clinical needs within cardiology, oncology and asthma. The group is a development stage company.
Executive Information
Name
Title
Email
John Thero
Sr. VP, CFO - Principal Financial, Accounting Officer
